Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population‐Based Cohort Study

Nannan Li, Jiangping Zeng, Z. H. Jia, Jinyuan Lu, Yuting Ma, Guangming Wang, Aibin Liang, Wenjun ZhangCancer 2025 · DOI

TL;DR

This study reveals that individuals diagnosed with a second primary multiple myeloma (2-MM) after a prior cancer exhibit a lower risk of dying specifically from multiple myeloma (MM) compared to those with a first primary MM (1-MM). However, these 2-MM patients face a higher overall mortality risk, with specific prior cancer types and their treatments influencing these outcomes, offering crucial insights for personalized survivorship care.

What Problem Does This Paper Address?

Multiple myeloma (MM) is a serious blood cancer, and with advancements in cancer care, more individuals are surviving initial diagnoses and living longer. This increased survivorship, however, brings a higher risk of developing secondary cancers. Specifically, second primary multiple myeloma (2-MM) is a growing concern. While it's known that having a prior cancer can negatively impact MM prognosis, there's a significant knowledge gap regarding how different types of prior primary malignancies (PPMs) and their treatments specifically influence the characteristics and survival outcomes of 2-MM patients. This paper aims to fill that gap by analyzing a large US population to understand these complex relationships and inform better care strategies.

Methods

This study employed a retrospective cohort design, analyzing data from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2021. The researchers defined 2-MM as an MM diagnosis occurring at least 6 months after a prior primary malignancy (PPM).

Key analytical approaches included:

  • Competing Risk Regression (Fine-Gray model): This was the primary method for estimating MM-specific mortality. It's crucial because it accounts for the fact that patients can die from causes other than MM (competing events), which is particularly relevant in cancer survivor populations.
  • Kaplan-Meier Method and Cox Regression: These standard survival analysis techniques were used to analyze all-cause mortality.
  • Propensity Score Matching: This technique was used to reduce bias by creating comparable groups of 1-MM and 2-MM patients, ensuring that observed differences were more likely due to the presence of a prior malignancy rather than other confounding factors.
  • Random Survival Forests (RSF): This machine learning approach was used to identify the relative importance of different factors (like MM group, age, treatment) in predicting MM-specific mortality.

The study also incorporated sensitivity analyses to ensure the robustness of findings, including all MM patients regardless of subsequent malignancies.

Datasets

The study utilized the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021). The SEER program is a comprehensive registry of cancer statistics in the United States, covering a large and diverse population. No new datasets were introduced.

Key Insights and Ideas

  • 2-MM Patients Have Better MM-Specific Survival, Worse Overall Survival: This is a central paradox. While 2-MM patients are less likely to die from MM, they are more likely to die from any cause. This suggests that the prior cancer or its treatment might confer some protection against MM progression, but the overall health burden of having had a prior cancer, or the cumulative effects of treatments, leads to a poorer general prognosis.
  • Specific PPMs Offer Protection Against MM Mortality: Certain prior cancers, such as soft tissue sarcomas, melanoma of the skin, corpus uteri, prostate, kidney and renal pelvis, and lymphoma, were associated with a significantly reduced risk of MM-specific mortality in 2-MM patients. This hints at potential shared biological mechanisms or immune responses that might be protective.
  • PPMs Increase Overall Mortality Risk: Conversely, many PPMs were linked to an increased risk of all-cause mortality in 2-MM patients, highlighting the long-term health consequences of prior cancers.
  • Treatment Modalities Have Differential Impacts: The impact of prior cancer treatments on MM outcomes is complex and not uniform. For instance, chemotherapy for prior lymphoma was linked to increased all-cause mortality, while radiotherapy for prior breast cancer and surgery for prior prostate cancer were associated with decreased all-cause mortality. This suggests that the specific treatment modality can have lasting effects.
  • Demographic Differences in 2-MM: 2-MM patients were generally older, more likely to be male, and more often White compared to 1-MM patients, suggesting potential differences in risk factors or diagnostic pathways.

Key Results

  • The study identified 74,932 1-MM patients and 6,465 2-MM patients.
  • 2-MM patients had a reduced risk of MM-specific mortality compared to 1-MM patients (adjusted SHR: 0.848).
  • Specific PPMs like soft tissue sarcomas (adjusted SHR: 0.323), melanoma of the skin (adjusted SHR: 0.776), prostate cancer (adjusted SHR: 0.876), and lymphoma (adjusted SHR: 0.760) were associated with reduced MM-specific mortality.
  • The median overall survival (OS) was shorter for the 2-MM cohort (41 months) compared to the 1-MM cohort (48 months).
  • Multiple PPMs were associated with increased risks of all-cause mortality.
  • Chemotherapy for prior lymphoma was associated with an increased all-cause mortality risk (adjusted HR: 1.426), while radiotherapy for prior breast cancer (adjusted HR: 0.742) and surgery for prior prostate cancer (adjusted HR: 0.749) were linked to decreased all-cause mortality.

Limitations and Future Work

The authors acknowledge several limitations:

  • Data Granularity: The SEER database lacks detailed information on clinical staging, cytogenetic abnormalities, and specific therapeutic regimens (e.g., exact drug dosages, treatment timing, radiation fields). This limits the depth of analysis for treatment modality effects.
  • Rare PPMs: Limited data for rare PPMs necessitate caution in interpreting findings for those specific subgroups.
  • Selection Bias: As with any retrospective study using registry data, potential selection biases exist, and the data only represents US residents formally entered into the registry.
  • Generalizability: The findings' external validity may require confirmation across diverse geographic settings.

Future work could focus on:

  • Investigating Genetic Factors: Exploring genetic alterations shared between MM and PPMs that might influence prognosis.
  • Detailed Treatment Analysis: Future studies with more detailed treatment data could provide a more comprehensive understanding of treatment modality impacts.
  • De-escalated Treatment Strategies: For 2-MM patients with favorable PPMs (like prostate cancer), de-escalated treatment strategies might be warranted.
  • Intensified Surveillance: For 2-MM patients with poorer OS profiles, intensified multidisciplinary surveillance and management are recommended.

Summary updated

Abstract

Compared to 1-MM, 2-MM exhibited distinct characteristics and survival outcomes in adults, which were associated with PPM types and their treatment modalities. These findings provide critical insights for risk stratification and survivorship care in US adults.
BibTeX
@inproceedings{li2025characteristics,
  author = {Nannan Li and Jiangping Zeng and Z. H. Jia and Jinyuan Lu and Yuting Ma and Guangming Wang and Aibin Liang and Wenjun Zhang},
  title = {{Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population‐Based Cohort Study}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1002/cam4.71393},
}
Figure